Bausch + Lomb Co. (NYSE:BLCO) Holdings Trimmed by Clark Estates Inc. NY

Clark Estates Inc. NY trimmed its position in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 4.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 687,500 shares of the company's stock after selling 31,000 shares during the period. Bausch + Lomb accounts for approximately 2.5% of Clark Estates Inc. NY's investment portfolio, making the stock its 9th biggest position. Clark Estates Inc. NY owned 0.20% of Bausch + Lomb worth $13,262,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Clearline Capital LP lifted its holdings in shares of Bausch + Lomb by 136.8% during the second quarter. Clearline Capital LP now owns 712,055 shares of the company's stock worth $10,339,000 after purchasing an additional 411,404 shares during the period. Whitebox Advisors LLC increased its stake in shares of Bausch + Lomb by 28.2% in the second quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company's stock valued at $22,447,000 after buying an additional 339,643 shares during the period. Rokos Capital Management LLP bought a new position in shares of Bausch + Lomb during the first quarter worth about $5,602,000. Point72 Asset Management L.P. lifted its stake in shares of Bausch + Lomb by 31.0% in the second quarter. Point72 Asset Management L.P. now owns 647,156 shares of the company's stock worth $9,397,000 after acquiring an additional 153,000 shares during the period. Finally, Point72 Europe London LLP boosted its holdings in Bausch + Lomb by 28.9% in the second quarter. Point72 Europe London LLP now owns 653,492 shares of the company's stock valued at $9,489,000 after acquiring an additional 146,583 shares during the last quarter. Institutional investors own 11.07% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on BLCO shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, October 31st. HC Wainwright lifted their price objective on Bausch + Lomb from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Evercore raised their target price on Bausch + Lomb from $15.50 to $17.00 and gave the stock an "in-line" rating in a research note on Thursday, August 1st. Citigroup boosted their price target on Bausch + Lomb from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Finally, Royal Bank of Canada increased their price target on Bausch + Lomb from $20.00 to $23.00 and gave the stock an "outperform" rating in a report on Tuesday, October 22nd. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $20.91.

Bausch + Lomb Stock Up 1.1 %

Shares of Bausch + Lomb stock traded up $0.22 during trading hours on Wednesday, reaching $19.97. The company's stock had a trading volume of 126,768 shares, compared to its average volume of 556,441. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The stock's fifty day simple moving average is $19.80 and its two-hundred day simple moving average is $17.10. The company has a market capitalization of $7.03 billion, a P/E ratio of -19.02, a P/E/G ratio of 1.92 and a beta of 0.46. Bausch + Lomb Co. has a one year low of $13.16 and a one year high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.01. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The company's quarterly revenue was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.22 EPS. On average, research analysts forecast that Bausch + Lomb Co. will post 0.59 earnings per share for the current year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.